Trial reportMarine drugs2026
Ascophyllan Supplementation Is Safe and Associated with Exploratory Modulation of Innate Immune Phenotypes, Biochemical Parameters, and the Gut Microbiome in a Randomized Pilot Trial.
Shohei Mizuno, Jorge Luis Espinoza, Lam Quang Vu, Hirona Banno, Yusuke Iida, Saki Shinohara, Do Tung Dac, Yuya Nakagami, Kaori Uchino, Tomohiro Horio and 7 more
Abstract readRandomized Controlled Trial
In one paragraphTrial report in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0002-4405-8808 Jorge Luis EspinozaFaculty of Health Sciences, Kanazawa University, Kodatsuno 5-11-18, Kanazawa 920-0942, Ishikawa, Japan.ORCID 0000-0002-1794-6666 Lam Quang VuDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0002-5440-1120 Hirona BannoDepartment of Central Clinical Laboratory, Aichi Medical University Hospital, Nagakute 480-1195, Aichi, Japan.
Yusuke IidaDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.
Saki ShinoharaDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.
Do Tung DacFaculty of Health Sciences, Kanazawa University, Kodatsuno 5-11-18, Kanazawa 920-0942, Ishikawa, Japan.ORCID 0009-0001-3007-2596 Yuya NakagamiDepartment of Central Clinical Laboratory, Aichi Medical University Hospital, Nagakute 480-1195, Aichi, Japan.
Kaori UchinoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0003-2983-2129 Tomohiro HorioDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0002-3485-6857 Ichiro HanamuraDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0002-6681-8927 Nobuhiro AsaiDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.
Megumi EnomotoDepartment of Central Clinical Laboratory, Aichi Medical University Hospital, Nagakute 480-1195, Aichi, Japan.
Hiroya TaniDepartment of Central Clinical Laboratory, Aichi Medical University Hospital, Nagakute 480-1195, Aichi, Japan.
Takayuki NakayamaDepartment of Blood Transfusion and Clinical Laboratory, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0003-2389-2542 Susumu SuzukiResearch Creation Support Center, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0002-1466-8824 Akiyoshi TakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.ORCID 0000-0002-1822-9976 Funding
Ministry of Education, Culture, Sports, Science and Technology #21K08427Ministry of Education, Culture, Sports, Science and Technology #24K11527
6 · The paper itselfAbstract
backgroundAscophyllan, a sulfated polysaccharide extracted from brown seaweed, has shown immunomodulatory and antioxidant effects in preclinical studies, yet human clinical evidence remains scarce. This randomized, double-blind, placebo-controlled pilot trial evaluated the safety and exploratory biological effects of daily ascophyllan supplementation in healthy adults.
methodsTwelve participants were randomized to receive either ascophyllan (
resultsAscophyllan supplementation proved well tolerated, with no adverse events observed and stable hematologic, renal, and biochemical parameters throughout the study. Exploratory longitudinal analyses suggested directional modulation of NK-cell-associated phenotypes during ascophyllan supplementation, including directional changes in CD57
conclusionsThese preliminary findings indicate that ascophyllan is safe and well tolerated in healthy adults and may be associated with modulation of innate immune phenotypes, subtle microbiome compositional differences, and directional changes in antioxidant capacity. Larger, adequately powered clinical trials are warranted to confirm these observations and further investigate potential biological and clinical effects.
Indexed as
Dietary SupplementsGastrointestinal MicrobiomeImmunity, InnatePolysaccharidesAdultAntioxidantsDouble-Blind MethodFemaleHumansKiller Cells, NaturalMaleMiddle AgedPhenotypePilot ProjectsRNA, Ribosomal, 16SYoung AdultAntioxidantsPolysaccharidesRNA, Ribosomal, 16Sascophyllanfunctional dietary polysaccharidegut microbiomeinnate immunitynatural killer cells
Identifiers
PMID42346798
PMCPMC13301280
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390